Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2013 07:00 ET | Source: Chimerix, Inc.

Chimerix to Announce Second Quarter Financial Results on August 14, 2013

DURHAM, N.C., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that it...
August 02, 2013 07:00 ET | Source: Chimerix, Inc.

Chimerix Elects Rodman L. Drake to Board of Directors

DURHAM, N.C., Aug. 2, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the...
July 02, 2013 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at JMP Securities Healthcare Conference

DURHAM, N.C., July 2, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that M....
June 25, 2013 17:00 ET | Source: Chimerix, Inc.

Chimerix to Join Russell Indexes on June 28, 2013

DURHAM, N.C., June 25, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it...
June 03, 2013 07:00 ET | Source: Chimerix, Inc.

Chimerix and BARDA Continue Collaboration on Development of CMX001 as a Medical Countermeasure Against Smallpox

DURHAM, N.C., June 3, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the...
May 16, 2013 08:00 ET | Source: Chimerix, Inc.

Chimerix's CMX001 Resistance Data Presented at the 26th International Conference on Antiviral Research

DURHAM, N.C., May 16, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, recently presented data...
May 13, 2013 06:00 ET | Source: Chimerix, Inc.

Chimerix Announces First Quarter 2013 Financial Results

DURHAM, N.C., May 13, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial...
May 10, 2013 10:37 ET | Source: Chimerix, Inc.

Data on Chimerix's CMX001 Selected for Two Oral Presentations at the 26th International Conference on Antiviral Research

DURHAM, N.C., May 10, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral...
May 06, 2013 08:00 ET | Source: Chimerix, Inc.

Chimerix to Announce First Quarter Financial Results on May 13, 2013

DURHAM, N.C., May 6, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that it...
April 29, 2013 08:00 ET | Source: Chimerix, Inc.

Chimerix Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With Life-Threatening Viral Infections

CMX001 demonstrated positive clinical activity against life-threatening adenovirus infection in patients enrolled in the CMX001 Compassionate Use Program A significant proportion of...

keyboard_arrow_left Previous Page